RxDoctor Payments Data

Jill Bryant, MD

Internal Medicine · Waycross, GANPI 1306820741

Payments from drug & device makers

$7,596in general payments, 2019–2025

Across 501 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$661
  • Pfizer$565
  • AbbVie$531
  • AstraZeneca$492
  • Lilly USA, LLC$409
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,591100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,596 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$797,679
Medicare patients
794
Services billed
28,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide158$174,048
MounjaroTirzepatide122$146,585
EliquisApixaban253$118,917
JardianceEmpagliflozin106$97,763
ProliaDenosumab40$68,271
TrulicityDulaglutide54$54,115
FarxigaDapagliflozin Propanediol56$37,168
JanuviaSitagliptin Phosphate73$32,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$29,400
Tresiba Flextouch U-200Insulin Degludec29$29,246
EntrestoSacubitril/Valsartan19$27,090
Tresiba Flextouch U-100Insulin Degludec48$26,115
Repatha SureclickEvolocumab32$20,768
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$20,140
VraylarCariprazine Hcl11$16,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$409$200,700176 claims
Novo NordiskOzempic, Rybelsus$1,344$189,343170 claims
PfizerEliquis, Premarin$565$125,556273 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$296$114,530138 claims
AmgenProlia$661$68,27140 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$124$57,81890 claims
AstraZenecaFarxiga, Breztri Aerosphere$492$45,65569 claims
AbbVieVraylar, Linzess, Synthroid$531$40,351192 claims
MerckJanuvia, Janumet$276$40,29984 claims
NovartisEntresto$197$27,09019 claims
Otsuka America Pharmaceutical, Inc.Rexulti$214$15,69817 claims
Johnson & JohnsonXarelto$182$14,07552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Waycross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →